Roivant Sciences ROIV
NASDAQ ROIV
$41.43 -0.05 (-0.12%)
As of: Sep 9, 2026 · 11:14 AM EDT

Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026)

Roivant Sciences' (ROIV) quarterly Non-Current Assets came in at $564.4 million in Q2 2026, up 35.4% on a YoY basis from $416.9 million in Q2 2025, and up 368797.39% quarter-over-quarter from $153000.0 in Q1 2026.

Analysis

Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has reported Non-Current Assets for 6 consecutive years, with $564.4 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Assets rose 35.4% year-over-year to $564.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 billion (up 5.82% YoY), and the FY2026 full-year result was $153000.0, down 24.26% from the prior year.
  • Non-Current Assets rose to $564.4 million in Q2 2026 per ROIV's latest filing, from $153000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.3 billion in Q4 2025 and bottomed at $153000.0 in Q1 2026.
  • Historically, Non-Current Assets has averaged $822.1 million across 5 years, with a median of $532.4 million in 2023.
  • The sharpest annual moves came in 2023 and 2025: Non-Current Assets jumped 257.11% in 2023, then slumped 98.6% in 2025.
  • Over 5 years, Non-Current Assets stood at $556.7 million in 2022, then surged by 257.11% to $2.0 billion in 2023, then gained by 17.73% to $2.3 billion in 2024, then jumped by 83.05% to $4.3 billion in 2025, then plunged by 86.83% to $564.4 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $564.4 million, $153000.0, and $4.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 211.68 Bn 197.69 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 180.84 Bn 177.66 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 132.30 Bn 124.45 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 82.50 Bn 74.50 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 61.49 Bn 56.31 Bn 1.37 Bn 1.96 Bn
6 Moderna 55.01 Bn 49.87 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 34.08 Bn 30.77 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.35 Bn 30.06 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.87 Bn 29.87 Bn 1.16 Mn 564.41 Mn
10 Insmed 27.84 Bn 26.68 Bn 358.27 Mn 468.65 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 564.41 Mn
Mar 31, 2026 153,000.00
Dec 31, 2025 4.28 Bn
Sep 30, 2025 550.95 Mn
Jun 30, 2025 416.85 Mn
Mar 31, 2025 202,000.00
Dec 31, 2024 2.34 Bn
Sep 30, 2024 404.91 Mn
Jun 30, 2024 494.95 Mn
Mar 31, 2024 14.42 Mn
Dec 31, 2023 1.99 Bn
Sep 30, 2023 513.92 Mn
Jun 30, 2023 575.49 Mn
Mar 31, 2023 591.02 Mn
Dec 31, 2022 556.73 Mn
Sep 30, 2022 500.67 Mn
Jun 30, 2022 560.96 Mn
Mar 31, 2022 438.61 Mn
Dec 31, 2021 511.84 Mn
Sep 30, 2021 547.15 Mn